4 hours ago
Rilzabrutinib shows promising remission rates in IgG4-related disease with minimal glucocorticoid use, offering a safer oral treatment option.
8 hours ago
Johnson & Johnson seeks FDA approval for lumateperone (CAPLYTA) to significantly reduce schizophrenia relapse risk. Company submits an sNDA.
8 hours ago
Whitley speaks to the plethora of available biologics, the choice paralysis that can accompany the wide range of options, and the future of the industry.
10 hours ago
New findings highlight upadacitinib's effectiveness in treating giant cell arteritis, showcasing lower infection rates and improved glucocorticoid tapering strategies.
11 hours ago
Drs. Richman and Wartman discuss the benefits of using predictive and diagnostic AI, while cautioning about the implicit risks of overreliance on early, imperfect technology.